{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-361895","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2026-08-24T12:15:14+00:00","discovered_at":"2026-08-24T12:20:02.304919+00:00","generated_at":"2026-08-24T12:20:06.336881+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Erasca gets FDA Fast Track for ERAS-0015 in metastatic pancreatic cancer","bullets":["FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma on Aug 24, 2026.","FTD may enable accelerated approval, priority review, and rolling review if criteria met.","Company plans phase 3 trial in pancreatic cancer and two registration-enabling trials in lung cancer.","FTD does not change approval standards; FDA may later revoke designation or not shorten review."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-361895","json":"https://secwatch.observer/filing/0001193125-26-361895.json","markdown":"https://secwatch.observer/filing/0001193125-26-361895.md","text":"https://secwatch.observer/filing/0001193125-26-361895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526361895/0001193125-26-361895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526361895/eras-20260824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-24T12:20:06.336881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}